

What is claimed is:

1. A method of treating or preventing a disorder caused by gastrointestinal motility dysfunction in a human  
5 which comprises administering to said human a therapeutically effective amount of (+) norcicapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

2. The method of claim 1, wherein said disorder is  
10 gastro-oesophageal reflux disease.

3. The method of claim 1, wherein said disorder is dyspepsia.

4. The method of claim 1, wherein said disorder is gastroparesis.

15 5. The method of claim 1, wherein said disorder is constipation.

6. The method of claim 1, wherein said disorder is intestinal pseudo-obstruction.

7. The method of claim 1, wherein said (+)  
20 norcicapride is administered orally.

8. The method of claim 7, wherein said (+)  
norcicapride is administered as a tablet.

9. The method of claim 1, wherein said (+)  
norcicapride is administered parenterally.

25 10. The method of claim 1, wherein said amount of (+)  
norcicapride, or a pharmaceutically acceptable salt thereof,  
is from about 0.5 to about 500 mg per day.

11. The method of claim 10, wherein said amount is from about 1 mg to about 250 mg per day.

30 12. The method of claim 11, wherein said amount is from about 5 mg to about 100 mg per day.

13. The method of claim 10, wherein said amount is administered in unit doses from one to four times a day.

14. The method of claim 1, wherein said amount of (+)  
35 norcicapride, or a pharmaceutically acceptable salt thereof,  
is at least about 90% by weight of the total weight of  
norcicapride.

15. A method of eliciting a prokinetic effect in a human to treat gastro-esophageal reflux disease in said human which comprises administering to said human a therapeutically effective amount of (+) norcicapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

16. The method of claim 15, wherein said (+) norcicapride is administered parenterally or orally as a tablet, a capsule or a liquid suspension.

10 17. The method of claim 16, wherein said amount of (+) norcicapride, or a pharmaceutically acceptable salt thereof, administered is from about 0.5 to about 500 mg per day.

18. The method of claim 17, wherein the amount administered is from about 1 mg to about 250 mg per day.

15 19. The method of claim 18, wherein the amount administered is from about 5 mg to 100 mg per day.

20. The method of claim 16, wherein said amount is administered in divided doses from one to four times per day.

21. The method of claim 15, wherein the amount of (+) norcicapride or a pharmaceutically acceptable salt thereof is at least about 90% by weight of the total weight of norcicapride.

22. The method of claim 15, wherein said (+) norcicapride or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer is administered with a pharmaceutically acceptable carrier.

23. The method of claim 15, wherein said (+) norcicapride or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer is administered with a pharmaceutically acceptable carrier.

24. A pharmaceutical composition suitable for administration to a human which comprises (+) norcicapride or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer; and a pharmaceutically acceptable carrier or excipient.